AUS
NZ
UK
CA
USA
IND
_02_06_2025_07_05_23_538703.jpg)
Highlights
Lisata Therapeutics and WARPNINE complete patient enrollment in iLSTA trial for certepetide in pancreatic cancer
Early data from ESMO-GI Congress reveals strong disease control with certepetide combination therapy
New US patent issued for certepetide, extending intellectual property protection
Operating in the biotechnology sector, Lisata Therapeutics is a clinical-stage pharmaceutical company focused on advancing therapies for solid tumors. The company’s recent developments align with broader trends in the global healthcare market, supported by its presence on indexes like the S&P/Tsx Composite Index, reflecting its expanding influence within clinical oncology research.
Progress in Pancreatic Cancer Research
Lisata Therapeutics recently announced the completion of patient enrollment for its Phase 1b/2a iLSTA clinical trial. This study evaluates certepetide in combination with standard chemotherapy and immunotherapy for patients with locally advanced, non-resectable pancreatic ductal adenocarcinoma. The trial is being conducted in collaboration with WARPNINE and is hosted at St John of God Subiaco Hospital in Western Australia, a center recognized for its clinical research initiatives.
Certepetide, the investigational therapy under review, is engineered to alter the tumor microenvironment. This alteration aims to enhance the uptake of anti-cancer treatments by improving drug penetration into solid tumors. Initial findings from the ESMO Gastrointestinal Cancers Congress, presented earlier this month, highlighted encouraging outcomes with consistent disease control in the early treatment cycles.
Enhancing Imaging Capabilities Through Global Collaboration
In addition to clinical trial progress, Lisata Therapeutics has entered a strategic collaboration with Kuva Labs to advance tumor imaging capabilities. This initiative is focused on refining the precision of tumor visualization, supporting more effective tracking of certepetide’s activity within the body. The integration of high-resolution imaging technologies is intended to provide greater clarity in evaluating therapeutic responses, particularly in challenging tumor environments.
Strengthening Patent Protection
Lisata Therapeutics was recently issued a new composition of matter patent by the United States Patent and Trademark Office for certepetide. The newly granted patent extends protection for the compound well into the next decade, contributing to the company's overall strategy for safeguarding its innovative assets. The patent underscores the unique characteristics of certepetide and strengthens the company’s position in the oncology pipeline space.
This development ensures that certepetide remains protected as the company progresses through clinical stages and explores additional applications in solid tumor treatment.
Momentum in Oncology Development
With multiple initiatives underway, Lisata Therapeutics continues to advance its mission of developing effective treatment options for patients facing advanced solid tumors. The combination of clinical progress, strategic collaborations, and reinforced intellectual property underscores the company's ongoing role in shaping the future of oncology therapeutics.
